Agomab prices $200M Nasdaq IPO at $16 a share

Got story updates? Submit your updates here. ›

Agomab Therapeutics NV, a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, has priced its initial public offering of 12,500,000 American Depositary Shares (ADSs) representing 12,500,000 of its common shares at $16.00 per ADS. The gross proceeds to Agomab from the offering are expected to be $200.0 million. The ADSs are expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol 'AGMB'.

Why it matters

Agomab's IPO represents a significant milestone for the company as it seeks to advance its pipeline of novel therapies for immunology and inflammatory diseases, which have high unmet medical needs. The $200 million in proceeds will help fund the company's ongoing clinical development efforts and support its growth as a publicly traded biopharmaceutical company.

The details

The IPO consists of 12,500,000 ADSs priced at $16.00 per ADS, with Agomab granting the underwriters a 30-day option to purchase an additional 1,875,000 ADSs. The offering is expected to close on February 9, 2026, subject to customary closing conditions. J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are acting as joint book-running managers for the offering.

• Agomab's ADSs are expected to begin trading on the Nasdaq Global Select Market on February 6, 2026.
• The offering is expected to close on February 9, 2026.

What’s next

The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.